Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 5Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Dexamethasone 238Lenalidomide 145daratumumab 123Bortezomib 101pomalidomide 86Calcium Dobesilate 76carfilzomib 74Cyclophosphamide 70Specimen Handling 42isatuximab 40Biopsy 40fludarabine 36belantamab mafodotin 36Magnetic Resonance Spectroscopy 35talquetamab 29dexamethasone acetate 27dexamethasone 21-phosphate 27Melphalan 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Multiple Myeloma × montelukast × 1 year × Clear all
NCT04268498 2026-03-24

ADVANCE

University of Miami

Phase 2 Active not recruiting
310 enrolled
Plasma cell

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

University of Miami

Phase 2 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

Phase 4 Recruiting
94 enrolled
Plasma cell

Multiple Myeloma

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡